Gene therapy for treating hemophilia B
Compositions for the treatment of hemophilia B are provided. In certain embodiments, the composition is a recombinant adeno-associated virus (rAAV) comprising an AAVrh10 capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5′ inverted terminal repeat (ITR), a coding sequence for a human Factor IX (F9) having coagulation function operably linked to regulatory elements which direct expression of the human Factor IX in liver cells, and an AAV 3′ ITR.
1. A recombinant adeno-associated virus (rAAV) useful as a liver-directed therapeutic for hemophilia B, said rAAV comprising an AAVrh10 capsid and a vector genome packaged therein, said vector genome comprising:
(a) an AAV 5′ inverted terminal repeat (ITR) sequence;
(b) a coding sequence encoding a human Factor IX (F9) having coagulation function operably linked to regulatory elements which direct expression of the human Factor IX protein in liver cells, wherein the coding sequence is SEQ ID NO: 2, and wherein the regulatory elements comprise (i) two copies of an alpha- 1 microglobulin/bikuin enhancer and (ii) a thyroid hormone binding globulin (TBG) promoter; and;
(c) an AAV 3′ ITR.
2. The rAAV according to claim 1 , wherein the encoded human Factor IX is the full-length protein about 461 amino acid residues in length.
3. The rAAV according to claim 1 , wherein the encoded human Factor IX comprises SEQ ID NO: 10.
4. The rAAV according to claim 1 , wherein the regulatory elements further comprise an intron.
5. The rAAV according to claim 4 , wherein the intron is a human beta globin IVS2 intron.
6. The rAAV according to claim 1 , wherein the regulatory elements further comprise a post-translational regulatory element and a polyA.
7. The rAAV according to claim 6 , wherein the post-translational regulatory element is a woodchuck post-transcriptional regulatory element.
8. The rAAV according to claim 6 , wherein the polyA is a bovine growth hormone polyA.
9. The rAAV according to claim 1 , wherein the AAV 5′ ITR and/or AAV3′ ITR is from AAV2.
10. The rAAV according to claim 1 , wherein the vector genome is about 4000 kilobases to about 4700 kilobases in size.
11. An aqueous suspension suitable for administration to a hemophilia B patient, said suspension comprising an aqueous suspending liquid and about 1×10 12 to about 3×10 13 genome copies (GC) of the rAAV/mL, wherein the GC are calculated as determined by optimized quantitative PCR (oqPCR), of a recombinant adeno-associated virus (rAAV) according to claim 1 .
12. The suspension according to claim 11 , wherein the suspension is suitable for intravenous injection.
13. The suspension according to claim 11 , wherein the suspension further comprises a surfactant, preservative, and/or buffer dissolved in the aqueous suspending liquid.
14. The suspension according to claim 11 , wherein the suspension comprises a non-ionic surfactant, a buffer solution, and has a pH of about 7 to about 8.
15. The suspension according to claim 14 , wherein the surfactant is a poloxomer.
16. The rAAV according to claim 1 , wherein the vector genome comprises nucleotides 1-3951 of SEQ ID NO:11.
17. The rAAV according to according to claim 1 , wherein:
the alpha-1 microglobulin/bikunin enhancer is SEQ ID NO:4; and
the thyroid hormone binding globulin promoter is SEQ ID NO:5.
18. The rAAV according to claim 17 , wherein the AAV 5′ ITR is SEQ ID NO:3, and the AAV 3′ ITR is SEQ ID NO:9.
19. The rAAV according to claim 1 , wherein the regulatory elements further comprise an intron of SEQ ID NO:6.
20. The rAAV according to claim 1 , wherein the regulatory elements further comprise a woodchuck post-transcriptional regulatory element of SEQ ID NO: 7.
21. The rAAV according to claim 1 , wherein the regulatory elements further comprising a polyA sequence of SEQ ID NO:8.